La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Evaxion Biotech Croissance future
Future contr ôle des critères 5/6
Evaxion Biotech is forecast to grow earnings and revenue by 61% and 57% per annum respectively while EPS is expected to grow by 93.2% per annum.
Informations clés
61.0%
Taux de croissance des bénéfices
93.2%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 30.4% |
| Taux de croissance des recettes | 57.0% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 15 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 29 | 4 | N/A | N/A | 3 |
| 12/31/2025 | 6 | -14 | N/A | N/A | 5 |
| 12/31/2024 | 1 | -11 | N/A | N/A | 4 |
| 6/30/2024 | 0 | -15 | N/A | N/A | N/A |
| 3/31/2024 | 0 | -15 | N/A | N/A | N/A |
| 12/31/2023 | 0 | -22 | -18 | -18 | N/A |
| 9/30/2023 | N/A | -24 | -22 | -22 | N/A |
| 6/30/2023 | N/A | -25 | -24 | -24 | N/A |
| 3/31/2023 | N/A | -24 | N/A | N/A | N/A |
| 12/31/2022 | N/A | -23 | -26 | -26 | N/A |
| 9/30/2022 | N/A | -25 | -25 | -24 | N/A |
| 6/30/2022 | N/A | -24 | -25 | -24 | N/A |
| 3/31/2022 | N/A | -26 | -27 | -26 | N/A |
| 12/31/2021 | N/A | -25 | -23 | -22 | N/A |
| 9/30/2021 | N/A | -20 | -23 | -22 | N/A |
| 6/30/2021 | N/A | -19 | -20 | -19 | N/A |
| 3/31/2021 | N/A | -16 | -14 | -14 | N/A |
| 12/31/2020 | N/A | -15 | -13 | -12 | N/A |
| 9/30/2020 | N/A | -14 | -10 | -10 | N/A |
| 12/31/2019 | N/A | -11 | -7 | -7 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: EVAX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Bénéfices vs marché: EVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.
Croissance élevée des bénéfices: EVAX is expected to become profitable in the next 3 years.
Chiffre d'affaires vs marché: EVAX's revenue (57% per year) is forecast to grow faster than the US market (8.8% per year).
Croissance élevée des revenus: EVAX's revenue (57% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if EVAX's Return on Equity is forecast to be high in 3 years time